Form 4: Tonix Pharmaceuticals Director Reports Fractional Share Disposal After Reverse Stock Split

Director James Treco reports the involuntary sale of 0.02 common stock shares due to fractional shares resulting from a reverse stock split.

Summary

• On February 5, 2025, Director James Treco reported a transaction involving Tonix Pharmaceuticals Holding Corp. common stock.
• The transaction involved the involuntary sale of 0.02 shares at a price of $0.30.
• This sale was a result of fractional shares arising from a reverse stock split.
• The reporting person, James Treco, is a director of Tonix Pharmaceuticals Holding Corp.

Sentiment

Score: 5

Explanation: The document reports a routine transaction (sale of fractional shares) following a reverse stock split, which is neither particularly positive nor negative.

Industry Context

Reverse stock splits are often used by companies to increase their stock price to meet minimum listing requirements or to make the stock more attractive to investors. The sale of fractional shares is a common consequence of reverse stock splits.

Stakeholder Impact

• The reverse stock split and subsequent sale of fractional shares may have a minor impact on shareholders.

Key Dates